Spots Global Cancer Trial Database for Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients

Official Title: A Phase 3, Randomized, Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Decitabine Combined With HAAG Regimen in Newly Diagnosed Acute Myeloid Leukemia Patients Younger Than 60 Years

Study ID: NCT04087967

Conditions

Acute Myeloid Leukemia

Induction Chemotherapy

Interventions

Decitabine plus HAAG regimen

Idarubicine plus Cytarabine regimen

Study Description

Brief Summary: The purpose of this study is to evaluate the safety and efficacy of DAC combined with HAAG regimen in the induction treatment of newly diagnosed AML patients younger than 60 years.

Detailed Description: This is a phase 3, randomized, controlled, multi-center study in newly diagnosed AML patients younger than 60. The patients will be randomized to receive either DAC combined with HAAG or IA regimen in the induction treatment.